{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T19:14:44Z","timestamp":1777058084547,"version":"3.51.4"},"reference-count":18,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Pharmaceutics"],"published-print":{"date-parts":[[2007,5]]},"DOI":"10.1016\/j.ijpharm.2006.12.011","type":"journal-article","created":{"date-parts":[[2006,12,15]],"date-time":"2006-12-15T12:26:20Z","timestamp":1166185580000},"page":"302-309","source":"Crossref","is-referenced-by-count":68,"title":["In vitro behavior of a phosphate ester prodrug of amprenavir in human intestinal fluids and in the Caco-2 system: Illustration of intraluminal supersaturation"],"prefix":"10.1016","volume":"336","author":[{"given":"Joachim","family":"Brouwers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Tack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Augustijns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpharm.2006.12.011_bib1","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/jps.20553","article-title":"Intraluminal drug and formulation behavior and integration in in vitro permeability estimation: a case study with amprenavir","volume":"95","author":"Brouwers","year":"2006","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2006.12.011_bib2","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1159\/000016350","article-title":"Effect of P-glycoprotein modulators on alkaline phosphatase activity in cultured rat hepatocytes","volume":"10","author":"Calhau","year":"2000","journal-title":"Cell Physiol. Biochem."},{"key":"10.1016\/j.ijpharm.2006.12.011_bib3","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.2165\/00003495-200464180-00014","article-title":"Fosamprenavir: a review of its use in the management of antiretroviral therapy-naive patients with HIV infection","volume":"64","author":"Chapman","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.ijpharm.2006.12.011_bib4","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1210\/jc.83.11.3951","article-title":"Alkaline phosphatase (EC 3.1.3. 1) in serum is inhibited by physiological concentrations of inorganic phosphate","volume":"83","author":"Coburn","year":"1998","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ijpharm.2006.12.011_bib5","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1177\/009127002401102803","article-title":"Pharmacokinetics of GW433908, a prodrug of amprenavir, in healthy male volunteers","volume":"42","author":"Falcoz","year":"2002","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ijpharm.2006.12.011_bib6","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1042\/bj1041011","article-title":"Studies on alkaline phosphatase. Inhibition by phosphate derivatives and the substrate specificity","volume":"104","author":"Fernley","year":"1967","journal-title":"Biochem. J."},{"key":"10.1016\/j.ijpharm.2006.12.011_bib7","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0169-409X(95)00103-E","article-title":"Improved oral delivery: solubility limitations overcome by the use of prodrugs","volume":"19","author":"Fleisher","year":"1996","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijpharm.2006.12.011_bib8","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1128\/AAC.48.3.791-798.2004","article-title":"Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir","volume":"48","author":"Furfine","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpharm.2006.12.011_bib9","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1023\/A:1023827017224","article-title":"Absorption rate limit considerations for oral phosphate prodrugs","volume":"20","author":"Heimbach","year":"2003","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpharm.2006.12.011_bib10","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0378-5173(03)00287-4","article-title":"Enzyme-mediated precipitation of parent drugs from their phosphate prodrugs","volume":"261","author":"Heimbach","year":"2003","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2006.12.011_bib11","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ijpharm.2004.01.014","article-title":"Effect of simulated intestinal fluid on drug permeability estimation across Caco-2 monolayers","volume":"274","author":"Ingels","year":"2004","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2006.12.011_bib12","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1093\/clinchem\/28.12.2426","article-title":"L-phenylalanine inhibition of human alkaline phosphatases with p-nitrophenyl phosphate as substrate","volume":"28","author":"Komoda","year":"1982","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ijpharm.2006.12.011_bib13","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1211\/0022357022511","article-title":"Predicting the precipitation of poorly soluble weak bases upon entry in the small intestine","volume":"56","author":"Kostewicz","year":"2004","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ijpharm.2006.12.011_bib14","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1023\/A:1020483911355","article-title":"Comparison of human duodenum and Caco-2 gene expression profiles for 12000 gene sequences tags and correlation with permeability of 26 drugs","volume":"19","author":"Sun","year":"2002","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpharm.2006.12.011_bib15","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1159\/000468804","article-title":"In vitro inhibition of alkaline phosphatase activities from intestine, bone, liver, and kidney by phenobarbital","volume":"46","author":"Tardivel","year":"1992","journal-title":"Enzyme"},{"key":"10.1016\/j.ijpharm.2006.12.011_bib16","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1023\/A:1022699920043","article-title":"Prediction of the oral absorption of low-permeability drugs using small intestine-like 2\/4\/A1 cell monolayers","volume":"20","author":"Tavelin","year":"2003","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpharm.2006.12.011_bib17","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2165\/00003088-200645020-00002","article-title":"Fosamprenavir: clinical pharmacokinetics and drug interactions of the amprenavir prodrug","volume":"45","author":"Wire","year":"2006","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ijpharm.2006.12.011_bib18","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1023\/A:1018939006780","article-title":"Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability","volume":"16","author":"Yu","year":"1999","journal-title":"Pharm. Res."}],"container-title":["International Journal of Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517306010696?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517306010696?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,19]],"date-time":"2020-04-19T08:35:48Z","timestamp":1587285348000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378517306010696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["S0378517306010696"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpharm.2006.12.011","relation":{},"ISSN":["0378-5173"],"issn-type":[{"value":"0378-5173","type":"print"}],"subject":[],"published":{"date-parts":[[2007,5]]}}}